IMLYGIC® (talimogene laherparepvec) is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery...READ MORE
Use this instructional guide to review efficacy, dosing, and administration details, and to get information about integrating IMLYGIC® into your practice.
/Page Content/DownloadList/Main Download Section/DownloadList/Download/Download Content/Download Scriban(1,15) : error : Unexpected exception when calling sc_link_info i_item CTALink
IMLYGIC® is shipped from select, authorized specialty distributors—use this guide to find a qualified distributor. Also find information on ordering options, the order and delivery schedule and product storage.
/Page Content/DownloadList/Main Download Section/DownloadList/Download/Download Content/Download Scriban(1,15) : error : Unexpected exception when calling sc_link_info i_item CTALink
Because of its special properties and storage requirements, IMLYGIC® is shipped on a fixed delivery schedule for coordination with patient scheduling. Download and print a copy of the schedule here for convenience.
/Page Content/DownloadList/Main Download Section/DownloadList/Download/Download Content/Download Scriban(1,15) : error : Unexpected exception when calling sc_link_info i_item CTALink
Get some key product information, including packaging details, information on ordering IMLYGIC®, and storage and handling requirements.
The Prescribing Information provides all of the requirements for handling IMLYGIC®. This Checklist is not intended to serve as a replacement for the Prescribing Information.
/Page Content/DownloadList/Main Download Section/DownloadList/Download/Download Content/Download Scriban(1,15) : error : Unexpected exception when calling sc_link_info i_item CTALink
IMPORTANT SAFETY INFORMATION
Please see full Prescribing Information and Medication Guide for IMLYGIC®.
INDICATION
IMLYGIC® is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Limitations of use: IMLYGIC® has not been shown to improve overall survival or have an effect on visceral metastases.
IMPORTANT SAFETY INFORMATION
Do not administer IMLYGIC® to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy, due to the risk of life-threatening disseminated herpetic infection.
Do not administer IMLYGIC® to pregnant patients.
Accidental exposure to IMLYGIC® may lead to transmission of IMLYGIC® and herpetic infection, including during preparation and administration. Health care providers, close contacts, pregnant women, and newborns should